Interactive Effects of Sodium and Potassium on Vascular Health in Older Adults
11 de junio de 2026 actualizado por: Andrea Lobene, Florida State University
Exploring the Interactive Effects of Sodium and Potassium Intake on Vascular Health in Older Adults
The goal of this clinical trial is to determine if a high potassium intake can counteract the harmful effects of excess sodium on endothelial function in older adults with no history of cardiometabolic disease. The main questions it aims to answer are:
- Can a high potassium intake attenuate dietary sodium-induced endothelial dysfunction in older adults.
- Do changes in endothelial function in response to alterations in sodium and potassium intake differ by sex.
Participants will participants will consume three controlled diets for 10 days each with a minimum 14-day washout between interventions. The order in which participants consume the diets will be randomized. The study diets will vary in sodium and potassium content. Measures of cardiovascular health (blood pressure, arterial stiffness, endothelial function) will be assessed at the end of each diet.
Descripción general del estudio
Estado
Reclutamiento
Condiciones
Intervención / Tratamiento
Descripción detallada
Cardiovascular health declines with age, especially in postmenopausal females.
High sodium diets are a major contributor to cardiovascular disease.
Unfortunately, reducing sodium intake can be challenging.
It is known that increasing potassium intake can improve cardiovascular disease risk factors in young adults, even if sodium intake remains high.
The investigators are hoping to show that potassium can improve cardiovascular health in the context of a high sodium diets in older adults.
In this study, participants will consume three 10-day controlled diets in a randomized order.
The study diets will include: 1) a low sodium (2,000 mg/day)/low potassium (2,000 mg/day) diet; 2) a high sodium (4,700 mg/day)/usual potassium diet; and 3) a high sodium/high potassium (4,700 mg/day).
All food will be provided to participants during these periods, and participants will be instructed not to consume any outside food or beverages.
Dietary interventions will be separated by a minimum two-week washout period.
Measurements of cardiovascular health will be collected at the end of each diet.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
30
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: FSU Ann's College
- Número de teléfono: 850-644-6685
Copia de seguridad de contactos de estudio
- Nombre: Andrea Lobene
- Número de teléfono: 850-644-1829
- Correo electrónico: alobene@fsu.edu
Ubicaciones de estudio
-
-
Florida
-
Tallahassee, Florida, Estados Unidos, 32306
- Reclutamiento
- Florida State University
-
Contacto:
- Andrea Lobene
- Número de teléfono: 850-644-1829
- Correo electrónico: alobene@fsu.edu
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- Adults ages 55-75 years
- At least one-year post-menopause (females)
- Willing and able to attend laboratory visits
Exclusion Criteria:
- BMI ≥35 kg/m2
- Seated blood pressure >135/85 mmHg
- Current diagnosis or history of cardiovascular disease, diabetes, renal disease, cancer, or major cardiovascular event (e.g. heart attack or stroke)
- Taking exogenous hormones or hormone replacement therapy
- Following a vegan or gluten free diet
- Significant weight loss (>10% of body weight) in the last 6 months, or actively trying to lose weight
- Current or recent use of a diuretic (within the past 6 months) (e.g. spironolactone, eplerenone)
- Current or recent use of a potassium binding medication (within the past 6 months)
- Current use of blood pressure lowering medications (e.g. ACE inhibitors, calcium channel blockers, diuretics, vasodilators, beta blockers, AngII receptor blockers)
- Current or recent use of the medication trimethoprim
- Elevated blood lipids (LDL cholesterol ≥190 mg/dL)
- Elevated serum potassium level (>5.1 mmol/L)
- Elevated BUN (>22 mg/dL)
- Elevated creatinine (>1.2 mg/dL)
- Low eGFR (<90 mL/min/1.73 m²)
- Current or recent use of tobacco, nicotine, or illicit drugs
- Radical hysterectomy or oophorectomy (females)
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: low Na/low K, high Na/low K, high Na/high K
Three 10-day controlled diets in randomized order, each varying in sodium and potassium content.
There is a minimum 2-week washout between diets.
|
On this intervention, participants will be given a diet that provides 2,000 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 4,700 mg K/day
|
|
Experimental: low Na/low K, high Na/high K, high Na/low K
Three 10-day controlled diets in randomized order, each varying in sodium and potassium content.
There is a minimum 2-week washout between diets.
|
On this intervention, participants will be given a diet that provides 2,000 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 4,700 mg K/day
|
|
Experimental: high Na/high K, low Na/low K, high Na/low K
Three 10-day controlled diets in randomized order, each varying in sodium and potassium content.
There is a minimum 2-week washout between diets.
|
On this intervention, participants will be given a diet that provides 2,000 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 4,700 mg K/day
|
|
Experimental: high Na/high K, high Na/low K, low Na/low K
Three 10-day controlled diets in randomized order, each varying in sodium and potassium content.
There is a minimum 2-week washout between diets.
|
On this intervention, participants will be given a diet that provides 2,000 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 4,700 mg K/day
|
|
Experimental: high Na/low K, low Na/low K, high Na/high K
Three 10-day controlled diets in randomized order, each varying in sodium and potassium content.
There is a minimum 2-week washout between diets.
|
On this intervention, participants will be given a diet that provides 2,000 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 4,700 mg K/day
|
|
Experimental: high Na/low K, high Na/high K, low Na/low K
Three 10-day controlled diets in randomized order, each varying in sodium and potassium content.
There is a minimum 2-week washout between diets.
|
On this intervention, participants will be given a diet that provides 2,000 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 2,000 mg K/day
On this intervention, participants will be given a diet that provides 4,700 mg Na/day and 4,700 mg K/day
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Endothelial function
Periodo de tiempo: "Day 11" after each of the three 10-day dietary interventions
|
Brachial artery flow-mediated dilation as measured in % dilation
|
"Day 11" after each of the three 10-day dietary interventions
|
|
Blood pressure
Periodo de tiempo: "Day 11" after each of the three 10-day dietary interventions
|
24-hour ambulatory blood pressure
|
"Day 11" after each of the three 10-day dietary interventions
|
|
Arterial stiffness
Periodo de tiempo: "Day 11" after each of the three 10-day dietary interventions
|
Carotid-femoral pulse wave velocity
|
"Day 11" after each of the three 10-day dietary interventions
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Andrea Lobene, Florida State University
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
24 de marzo de 2026
Finalización primaria (Estimado)
30 de junio de 2027
Finalización del estudio (Estimado)
30 de junio de 2027
Fechas de registro del estudio
Enviado por primera vez
9 de junio de 2026
Primero enviado que cumplió con los criterios de control de calidad
11 de junio de 2026
Publicado por primera vez (Actual)
15 de junio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
15 de junio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
11 de junio de 2026
Última verificación
1 de junio de 2026
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- STUDY00006676
- UF-FSU CTSA Career Development (Otro número de subvención/financiamiento: UF-FSU Clinical and Translational Science Award)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .